[{"id":"5561c46c-9fe6-437d-a39f-ed6b0feba556","acronym":"","url":"https://clinicaltrials.gov/study/NCT06998940","created_at":"2025-06-07T14:48:14.371Z","updated_at":"2025-06-07T14:48:14.371Z","phase":"Phase 3","brief_title":"Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations","source_id_and_acronym":"NCT06998940","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Vectibix (panitumumab) • albumin-bound paclitaxel • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • fluorouracil topical"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 94","initiation":"Initiation: 01/06/2026","start_date":" 01/06/2026","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2025-05-31"},{"id":"0cab49cd-f269-4139-a170-355e5106eb01","acronym":"","url":"https://clinicaltrials.gov/study/NCT05564377","created_at":"2022-10-03T15:56:45.241Z","updated_at":"2025-02-25T12:29:02.892Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","source_id_and_acronym":"NCT05564377","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Ibrance (palbociclib) • paclitaxel • Vectibix (panitumumab) • Koselugo (selumetinib) • Nerlynx (neratinib) • Piqray (alpelisib) • Lumakras (sotorasib) • Mektovi (binimetinib) • nilotinib • fulvestrant • oxaliplatin • ipatasertib (RG7440) • leucovorin calcium • fluorouracil topical"],"overall_status":"Recruiting","enrollment":" Enrollment 2900","initiation":"Initiation: 04/07/2023","start_date":" 04/07/2023","primary_txt":" Primary completion: 07/01/2030","primary_completion_date":" 07/01/2030","study_txt":" Completion: 07/01/2030","study_completion_date":" 07/01/2030","last_update_posted":"2025-02-24"},{"id":"28c966c6-aa0a-48ec-89d0-5286ecccf723","acronym":"","url":"https://clinicaltrials.gov/study/NCT02912559","created_at":"2021-01-18T14:17:52.733Z","updated_at":"2025-02-25T12:26:32.593Z","phase":"Phase 3","brief_title":"Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair","source_id_and_acronym":"NCT02912559","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MLH1 • MSH6 • MSH2 • CD4","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MLH1 • MSH6 • MSH2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • 5-fluorouracil • Cotellic (cobimetinib) • oxaliplatin • leucovorin calcium • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 700","initiation":"Initiation: 10/16/2017","start_date":" 10/16/2017","primary_txt":" Primary completion: 04/02/2025","primary_completion_date":" 04/02/2025","study_txt":" Completion: 04/02/2025","study_completion_date":" 04/02/2025","last_update_posted":"2025-02-24"},{"id":"c79faf97-f729-4398-957b-5d83e409d779","acronym":"COMMIT","url":"https://clinicaltrials.gov/study/NCT02997228","created_at":"2021-01-18T14:45:08.921Z","updated_at":"2025-02-25T12:26:35.429Z","phase":"Phase 3","brief_title":"Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study","source_id_and_acronym":"NCT02997228 - COMMIT","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" PD-L1 expression • BRAF V600E • MSI-H/dMMR","tags":["PD-L1 • MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF V600E • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • 5-fluorouracil • oxaliplatin • Aybintio (bevacizumab biosimilar) • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • fluorouracil topical • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 01/19/2018","start_date":" 01/19/2018","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-24"},{"id":"876c2e70-4925-4835-9b88-46d9ace36858","acronym":"ComboMATCH Treatment Trial","url":"https://clinicaltrials.gov/study/NCT05564403","created_at":"2022-11-26T21:57:48.468Z","updated_at":"2025-02-25T13:41:17.315Z","phase":"Phase 2","brief_title":"Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)","source_id_and_acronym":"NCT05564403 - ComboMATCH Treatment Trial","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MAPK1","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["MAPK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • oxaliplatin • leucovorin calcium • fluorouracil topical"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 02/09/2024","start_date":" 02/09/2024","primary_txt":" Primary completion: 01/21/2026","primary_completion_date":" 01/21/2026","study_txt":" Completion: 01/21/2026","study_completion_date":" 01/21/2026","last_update_posted":"2025-02-21"},{"id":"8e80751c-1262-45dc-bec5-fce7b2699448","acronym":"","url":"https://clinicaltrials.gov/study/NCT00217737","created_at":"2021-01-18T00:44:25.249Z","updated_at":"2025-02-25T14:39:13.469Z","phase":"Phase 3","brief_title":"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer","source_id_and_acronym":"NCT00217737","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • MSH2","pipe":"","alterations":" ","tags":["MSI • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • fluorouracil topical • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 3610","initiation":"Initiation: 09/06/2005","start_date":" 09/06/2005","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2025-02-14"},{"id":"6858793b-66b6-4bd1-8de9-e5db913af128","acronym":"","url":"https://clinicaltrials.gov/study/NCT03533582","created_at":"2021-01-18T17:24:25.522Z","updated_at":"2025-02-25T15:10:48.947Z","phase":"Phase 3","brief_title":"Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery","source_id_and_acronym":"NCT03533582","lead_sponsor":"Children's Oncology Group","biomarkers":" SMARCB1 • AFP","pipe":" | ","alterations":" AFP elevation","tags":["SMARCB1 • AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFP elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gemcitabine • sorafenib • 5-fluorouracil • doxorubicin hydrochloride • oxaliplatin • etoposide IV • irinotecan • vincristine • daunorubicin • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 537","initiation":"Initiation: 05/24/2018","start_date":" 05/24/2018","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-13"},{"id":"bcfa1353-7be6-4150-b82c-bf13212f8a0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05836584","created_at":"2023-05-01T14:03:52.795Z","updated_at":"2025-02-25T15:13:28.038Z","phase":"Phase 2","brief_title":"Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer","source_id_and_acronym":"NCT05836584","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • docetaxel • capecitabine • oxaliplatin • leucovorin calcium • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 12/06/2023","start_date":" 12/06/2023","primary_txt":" Primary completion: 10/31/2027","primary_completion_date":" 10/31/2027","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2025-02-13"},{"id":"dc334b0f-8b5c-4b2f-8468-f243cf63a6a0","acronym":"NCI-2022-09458","url":"https://clinicaltrials.gov/study/NCT05627635","created_at":"2022-11-25T15:58:22.182Z","updated_at":"2025-02-25T15:20:07.740Z","phase":"Phase 1/2","brief_title":"FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05627635 - NCI-2022-09458","lead_sponsor":"City of Hope Medical Center","biomarkers":" POLE","pipe":" | ","alterations":" POLE mutation","tags":["POLE"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e POLE mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • oxaliplatin • leucovorin calcium • balstilimab (AGEN2034) • botensilimab (AGEN1181) • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/03/2023","start_date":" 05/03/2023","primary_txt":" Primary completion: 10/07/2025","primary_completion_date":" 10/07/2025","study_txt":" Completion: 10/07/2025","study_completion_date":" 10/07/2025","last_update_posted":"2025-02-12"},{"id":"205a8549-254c-458b-bd69-60477d827fd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04380545","created_at":"2023-12-11T15:16:05.793Z","updated_at":"2025-02-25T15:18:37.255Z","phase":"Phase 1/2","brief_title":"Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer","source_id_and_acronym":"NCT04380545","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • fluorouracil topical • Novaferon (recombinant anti-tumor and anti-virus protein)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/13/2021","start_date":" 01/13/2021","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2025-02-11"},{"id":"424f1715-a08a-4e86-a255-1bc30e3c69e6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03203525","created_at":"2021-01-18T15:47:47.088Z","updated_at":"2025-02-25T15:42:56.837Z","phase":"Phase 1","brief_title":"Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer","source_id_and_acronym":"NCT03203525","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PIK3CA • PTEN","pipe":" | ","alterations":" PIK3CA mutation","tags":["PIK3CA • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • temsirolimus • pegylated liposomal doxorubicin • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • fluorouracil topical • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar) • doxorubicin liposomal"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 06/23/2020","start_date":" 06/23/2020","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-10"},{"id":"b3d6c3c2-daaa-494a-aacb-7469cd76f192","acronym":"","url":"https://clinicaltrials.gov/study/NCT04929028","created_at":"2021-06-18T23:52:29.721Z","updated_at":"2025-02-25T16:32:30.069Z","phase":"Phase 2","brief_title":"Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer","source_id_and_acronym":"NCT04929028","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • PD-1 • IFNG • CD4","pipe":" | ","alterations":" PD-1 expression","tags":["PD-L1 • PD-1 • IFNG • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • 5-fluorouracil • capecitabine • mitomycin • Jelmyto (mitomycin urothelial gel) • fluorouracil topical • ABP 206 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/09/2022","start_date":" 08/09/2022","primary_txt":" Primary completion: 09/15/2029","primary_completion_date":" 09/15/2029","study_txt":" Completion: 09/15/2029","study_completion_date":" 09/15/2029","last_update_posted":"2025-02-07"},{"id":"8ba4b2c4-2d3e-460e-9a2f-77116f701fa8","acronym":"S1513","url":"https://clinicaltrials.gov/study/NCT02890355","created_at":"2021-01-18T14:11:10.280Z","updated_at":"2025-02-25T16:36:47.130Z","phase":"Phase 2","brief_title":"FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer","source_id_and_acronym":"NCT02890355 - S1513","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • HRD • CEACAM5","pipe":" | ","alterations":" HRD","tags":["BRCA1 • BRCA2 • HRD • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • veliparib (ABT-888) • leucovorin calcium • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 123","initiation":"Initiation: 09/01/2016","start_date":" 09/01/2016","primary_txt":" Primary completion: 05/01/2019","primary_completion_date":" 05/01/2019","study_txt":" Completion: 03/05/2025","study_completion_date":" 03/05/2025","last_update_posted":"2025-02-06"},{"id":"b5993f06-cb2c-4080-9676-30541427ea90","acronym":"","url":"https://clinicaltrials.gov/study/NCT00980460","created_at":"2021-01-18T03:49:34.064Z","updated_at":"2025-02-25T16:50:58.740Z","phase":"Phase 3","brief_title":"Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer","source_id_and_acronym":"NCT00980460","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AFP","pipe":" | ","alterations":" AFP elevation","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFP elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • 5-fluorouracil • doxorubicin hydrochloride • irinotecan • temsirolimus • vincristine • fluorouracil topical • dexrazoxane"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 236","initiation":"Initiation: 09/14/2009","start_date":" 09/14/2009","primary_txt":" Primary completion: 06/30/2020","primary_completion_date":" 06/30/2020","study_txt":" Completion: 03/05/2025","study_completion_date":" 03/05/2025","last_update_posted":"2025-02-04"},{"id":"4346ba5f-67b8-4706-8e12-549591ad58c7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06696768","created_at":"2025-02-25T20:15:51.863Z","updated_at":"2025-02-25T20:15:51.863Z","phase":"Phase 1","brief_title":"Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer","source_id_and_acronym":"NCT06696768","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IFNG • IL6 • CCL2 • CXCL1 • IRAK4","pipe":"","alterations":" ","tags":["IFNG • IL6 • CCL2 • CXCL1 • IRAK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • oxaliplatin • Aybintio (bevacizumab biosimilar) • leucovorin calcium • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • emavusertib (CA-4948) • fluorouracil topical"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 02/28/2025","start_date":" 02/28/2025","primary_txt":" Primary completion: 10/31/2025","primary_completion_date":" 10/31/2025","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2025-01-16"},{"id":"20ec0814-6de7-4db9-a034-30ef491a8c51","acronym":"","url":"https://clinicaltrials.gov/study/NCT05526924","created_at":"2022-09-02T17:00:19.091Z","updated_at":"2025-02-25T16:27:01.989Z","phase":"Phase 1","brief_title":"Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer","source_id_and_acronym":"NCT05526924","lead_sponsor":"University of Chicago","biomarkers":" PD-L1 • PD-1","pipe":"","alterations":" ","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • Partruvix (pamiparib) • hydroxyurea • fluorouracil topical"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/07/2023","start_date":" 03/07/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-11-22"},{"id":"b90611f6-d5aa-4754-9793-ea6b3cb720a3","acronym":"EA2183","url":"https://clinicaltrials.gov/study/NCT04248452","created_at":"2021-01-18T20:38:53.831Z","updated_at":"2025-02-25T16:32:04.439Z","phase":"Phase 3","brief_title":"Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body","source_id_and_acronym":"NCT04248452 - EA2183","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" HER-2 • CD4","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • fluorouracil topical"],"overall_status":"Recruiting","enrollment":" Enrollment 314","initiation":"Initiation: 05/26/2020","start_date":" 05/26/2020","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 03/31/2028","study_completion_date":" 03/31/2028","last_update_posted":"2024-11-05"},{"id":"3513fc32-93ba-4272-be45-5e294da2ba02","acronym":"","url":"https://clinicaltrials.gov/study/NCT03970252","created_at":"2024-05-07T20:27:15.331Z","updated_at":"2025-02-25T14:28:23.674Z","phase":"Phase 1","brief_title":"Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer","source_id_and_acronym":"NCT03970252","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" IFNG","pipe":" | ","alterations":" IFNG-L","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IFNG-L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • oxaliplatin • irinotecan • leucovorin calcium • fluorouracil topical"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 07/24/2019","start_date":" 07/24/2019","primary_txt":" Primary completion: 05/25/2024","primary_completion_date":" 05/25/2024","study_txt":" Completion: 05/25/2024","study_completion_date":" 05/25/2024","last_update_posted":"2024-08-09"},{"id":"0bfa2ff0-2ec2-4458-9d27-cc84a6f03c25","acronym":"","url":"https://clinicaltrials.gov/study/NCT05651594","created_at":"2022-12-15T15:58:40.811Z","updated_at":"2024-07-02T16:34:25.750Z","phase":"Phase 2","brief_title":"Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT05651594","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • oxaliplatin • leucovorin calcium • fluorouracil topical"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 03/07/2023","start_date":" 03/07/2023","primary_txt":" Primary completion: 03/30/2026","primary_completion_date":" 03/30/2026","study_txt":" Completion: 03/30/2026","study_completion_date":" 03/30/2026","last_update_posted":"2024-06-14"},{"id":"0ce065b0-7320-4b49-acc1-1b38bcc23ffc","acronym":"SHIELD-RT","url":"https://clinicaltrials.gov/study/NCT03775265","created_at":"2021-01-18T18:40:31.838Z","updated_at":"2024-07-02T16:34:37.434Z","phase":"Phase 3","brief_title":"Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer","source_id_and_acronym":"NCT03775265 - SHIELD-RT","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD4","pipe":"","alterations":" ","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tecentriq (atezolizumab) • gemcitabine • 5-fluorouracil • mitomycin • Jelmyto (mitomycin urothelial gel) • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 475","initiation":"Initiation: 06/03/2019","start_date":" 06/03/2019","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-06-07"},{"id":"753d5f8f-02a0-4ca0-9711-5eef163c02e4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03784326","created_at":"2021-01-18T18:42:52.626Z","updated_at":"2024-07-02T16:34:58.959Z","phase":"Phase 2","brief_title":"Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma","source_id_and_acronym":"NCT03784326","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • 5-fluorouracil • oxaliplatin • tiragolumab (RG6058) • fluorouracil topical"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/19/2019","start_date":" 02/19/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-04"},{"id":"8fc59072-be3e-4c35-92de-8a0598e1cf53","acronym":"","url":"https://clinicaltrials.gov/study/NCT00082706","created_at":"2021-01-18T00:13:59.383Z","updated_at":"2024-07-02T16:35:02.799Z","phase":"Phase 2","brief_title":"Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant","source_id_and_acronym":"NCT00082706","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • 5-fluorouracil • leucovorin calcium • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 04/23/2003","start_date":" 04/23/2003","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-17"},{"id":"cdacc270-2f12-47f1-ad69-ceb4bc5981ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT03337087","created_at":"2021-01-18T16:29:08.233Z","updated_at":"2024-07-02T16:35:02.682Z","phase":"Phase 1/2","brief_title":"Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer","source_id_and_acronym":"NCT03337087","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" BRCA1 • BRCA2 • HRD • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HRD • PALB2 mutation • HRD + BRCA1 mutation","tags":["BRCA1 • BRCA2 • HRD • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HRD • PALB2 mutation • HRD + BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Rubraca (rucaparib) • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/02/2018","start_date":" 11/02/2018","primary_txt":" Primary completion: 03/31/2021","primary_completion_date":" 03/31/2021","study_txt":" Completion: 08/09/2025","study_completion_date":" 08/09/2025","last_update_posted":"2024-05-17"},{"id":"50c58012-9b92-4096-929a-64264a8757b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04761614","created_at":"2024-05-16T20:32:16.261Z","updated_at":"2024-07-02T16:35:03.341Z","phase":"Phase 1","brief_title":"Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT04761614","lead_sponsor":"Ning Jin","biomarkers":" IFNG • IL6 • CRP • FCGRT • LIF","pipe":"","alterations":" ","tags":["IFNG • IL6 • CRP • FCGRT • LIF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • oxaliplatin • leucovorin calcium • fluorouracil topical • riluzole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 04/02/2021","start_date":" 04/02/2021","primary_txt":" Primary completion: 05/06/2023","primary_completion_date":" 05/06/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-16"}]